These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Changes in compulsion and anxiety symptoms with nicotine transdermal patches in non-smoking obsessive-compulsive disorder patients. Salín-Pascual RJ; Basañez-Villa E Rev Invest Clin; 2003; 55(6):650-4. PubMed ID: 15011734 [TBL] [Abstract][Full Text] [Related]
23. A pilot study of vagus nerve stimulation (VNS) for treatment-resistant anxiety disorders. George MS; Ward HE; Ninan PT; Pollack M; Nahas Z; Anderson B; Kose S; Howland RH; Goodman WK; Ballenger JC Brain Stimul; 2008 Apr; 1(2):112-21. PubMed ID: 20633378 [TBL] [Abstract][Full Text] [Related]
24. The role of early maladaptive schemas in predicting exposure and response prevention outcome for obsessive-compulsive disorder. Haaland AT; Vogel PA; Launes G; Haaland VØ; Hansen B; Solem S; Himle JA Behav Res Ther; 2011 Nov; 49(11):781-8. PubMed ID: 21920500 [TBL] [Abstract][Full Text] [Related]
25. Development and psychometric evaluation of the Yale-Brown Obsessive-Compulsive Scale--Second Edition. Storch EA; Rasmussen SA; Price LH; Larson MJ; Murphy TK; Goodman WK Psychol Assess; 2010 Jun; 22(2):223-32. PubMed ID: 20528050 [TBL] [Abstract][Full Text] [Related]
26. Demographic and clinical characteristics associated with treatment status in family members with obsessive-compulsive disorder. Cullen B; Samuels JF; Pinto A; Fyer AJ; McCracken JT; Rauch SL; Murphy DL; Greenberg BD; Knowles JA; Piacentini J; Bienvenu OJ; Grados MA; Riddle MA; Rasmussen SA; Pauls DL; Willour VL; Shugart YY; Liang KY; Hoehn-Saric R; Nestadt G Depress Anxiety; 2008; 25(3):218-24. PubMed ID: 17345603 [TBL] [Abstract][Full Text] [Related]
27. Schema therapy augmented exposure and response prevention in patients with obsessive-compulsive disorder: Feasibility and efficacy of a pilot study. Thiel N; Jacob GA; Tuschen-Caffier B; Herbst N; Külz AK; Hertenstein E; Nissen C; Voderholzer U J Behav Ther Exp Psychiatry; 2016 Sep; 52():59-67. PubMed ID: 27016846 [TBL] [Abstract][Full Text] [Related]
28. Cognitive-coping therapy for obsessive-compulsive disorder: a randomized controlled trial. Ma JD; Wang CH; Li HF; Zhang XL; Zhang YL; Hou YH; Liu XH; Hu XZ J Psychiatr Res; 2013 Nov; 47(11):1785-90. PubMed ID: 23988179 [TBL] [Abstract][Full Text] [Related]
29. The relation of psychogenic excoriation with psychiatric disorders: a comparative study. Calikuşu C; Yücel B; Polat A; Baykal C Compr Psychiatry; 2003; 44(3):256-61. PubMed ID: 12764714 [TBL] [Abstract][Full Text] [Related]
31. Change in metacognitions predicts outcome in obsessive-compulsive disorder patients undergoing treatment with exposure and response prevention. Solem S; Håland AT; Vogel PA; Hansen B; Wells A Behav Res Ther; 2009 Apr; 47(4):301-7. PubMed ID: 19203749 [TBL] [Abstract][Full Text] [Related]
32. The relationship between metacognitions and insight in obsessive-compulsive disorder. Önen S; Karakaş Uğurlu G; Çayköylü A Compr Psychiatry; 2013 Jul; 54(5):541-8. PubMed ID: 23312877 [TBL] [Abstract][Full Text] [Related]
33. A randomized controlled trial of cognitive therapy versus intensive behavior therapy in obsessive compulsive disorder. Cottraux J; Note I; Yao SN; Lafont S; Note B; Mollard E; Bouvard M; Sauteraud A; Bourgeois M; Dartigues JF Psychother Psychosom; 2001; 70(6):288-97. PubMed ID: 11598428 [TBL] [Abstract][Full Text] [Related]
34. [A standardized cognitive-behavioural group treatment program for obsessive compulsive disorder: preliminary outcomes]. Bouvard M Encephale; 2002; 28(5 Pt 1):439-46. PubMed ID: 12386546 [TBL] [Abstract][Full Text] [Related]
35. [Can the efficacy of behavioral and cognitive therapy for obsessive compulsive disorder be augmented by innovative computerized adjuvant?]. Morgiève M; N'Diaye K; Clair AH; Pelissolo A; Mallet L Encephale; 2016 Oct; 42(5):402-409. PubMed ID: 27109326 [TBL] [Abstract][Full Text] [Related]
36. A comparison of symptom dimensions for obsessive compulsive disorder and obsessive compulsive-related disorders. Say Öcal D; Özdel K; Şafak Y; Kekilli Karnaz Y; Kısa C PLoS One; 2019; 14(7):e0218955. PubMed ID: 31276509 [TBL] [Abstract][Full Text] [Related]
37. Factors associated with the duration of untreated illness among patients with obsessive compulsive disorder. Poyraz CA; Turan Ş; Sağlam NG; Batun GÇ; Yassa A; Duran A Compr Psychiatry; 2015 Apr; 58():88-93. PubMed ID: 25596625 [TBL] [Abstract][Full Text] [Related]
38. Obsessive-compulsive adults with and without childhood ADHD symptoms. Tan O; Metin B; Metin S Atten Defic Hyperact Disord; 2016 Sep; 8(3):131-8. PubMed ID: 27056070 [TBL] [Abstract][Full Text] [Related]
39. Body dysmorphic disorder in patients with obsessive-compulsive disorder: prevalence and clinical correlates. Conceição Costa DL; Chagas Assunção M; Arzeno Ferrão Y; Archetti Conrado L; Hajaj Gonzalez C; Franklin Fontenelle L; Fossaluza V; Constantino Miguel E; Rodrigues Torres A; Gedanke Shavitt R Depress Anxiety; 2012 Nov; 29(11):966-75. PubMed ID: 22815241 [TBL] [Abstract][Full Text] [Related]
40. A study of cognitive function in treatment-refractory obsessive-compulsive disorder treated with capsulotomy. Gong F; Li P; Li B; Zhang S; Zhang X; Yang S; Liu H; Wang W J Neurosurg; 2018 Feb; 128(2):583-595. PubMed ID: 28338440 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]